Pharmobedient Consulting
As of the edition of 20 October 2026, Pharmobedient Consulting runs 14 drugs, 14 of them marketed.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 14 |
| Total | 14 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Zidovudine | none listed | 0 |
| Albuterol | none listed | 2 |
| Triamcinolone acetonide | none listed | 3 |
| Furosemide | none listed | 2 |
| Acyclovir | none listed | 0 |
| Clobetasol propionate | none listed | 2 |
| Torsemide | none listed | 1 |
| Promethazine | none listed | 1 |
| Cefoxitin | none listed | 0 |
| Butenafine | none listed | 0 |
| Flunisolide | none listed | 1 |
| Sulfanilamide | none listed | 0 |
| Butabarbital | none listed | 0 |
| Oxymetholone | none listed | 0 |
A route B row is one company at one target.